United Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026
United Therapeutics announced that the pivotal TETON-1 Phase 3 study of nebulized Tyvaso for idiopathic pulmonary fibrosis (IPF) met its primary endpoint, showing statistically significant preservation of lung function (FVC) versus placebo. The results, published in The New England Journal of Medicine, also showed a 33% reduction in the risk of clinical worsening. Combined analysis with TETON-2 confirmed these benefits and showed a 48% reduction in acute IPF exacerbations.
Key figures
- Drug Name
- Tyvaso (treprostinil)
- Phase Of Trial
- Phase 3
- Fvc change tyvaso
- -43.3 mL
- Fvc change placebo
- -196.2 mL
- Patient count teton1
- 598
- Study duration weeks
- 52
- Fvc between group diff
- 130.1 mL
- Us ipf patient estimate
- 100,000
- Clinical worsening risk reduction
- 33%
- Acute exacerbation risk reduction combined
- 48%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.